Comprehensive Stock Comparison
Compare Addus HomeCare Corporation (ADUS) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ADUS | 23.2% revenue growth vs FMS's 1.5% |
| Value | ADUS | PEG 0.74 vs 1.94 |
| Quality / Margins | ADUS | 6.7% net margin vs FMS's 5.0% |
| Stability / Safety | FMS | Beta 0.40 vs ADUS's 0.41 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ADUS | +8.1% vs FMS's +0.2% |
| Efficiency (ROA) | ADUS | 6.7% ROA vs FMS's 3.2%, ROIC 8.8% vs 5.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Valuation efficiency (growth/$)
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Addus HomeCare is a provider of in-home care services for elderly, chronically ill, and disabled individuals across the United States. It generates revenue primarily through government reimbursement programs — with Medicaid accounting for roughly 80% of revenue — supplemented by Medicare, private insurance, and private-pay clients across its personal care, hospice, and home health segments. The company's competitive advantage lies in its established relationships with state Medicaid agencies and its scale as one of the largest home care providers, which creates barriers to entry and operational efficiencies.
Fresenius Medical Care is a global leader in dialysis care and products for patients with chronic kidney failure. It generates revenue through two main segments: dialysis services (about 75% of revenue) from its network of outpatient clinics and hospital contracts, and dialysis products (about 25%) including machines, dialyzers, and related supplies. The company's key advantage is its vertically integrated model—combining clinics, products, and services—which creates patient stickiness and economies of scale in the capital-intensive dialysis industry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADUS leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). FMS leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.
Financial Metrics (TTM)
FMS is the larger business by revenue, generating $19.6B annually — 13.8x ADUS's $1.4B. Profitability is closely matched — net margins range from 6.7% (ADUS) to 5.0% (FMS). On growth, ADUS holds the edge at +25.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ADUSAddus HomeCare Co… | FMSFresenius Medical… |
|---|---|---|
| RevenueTrailing 12 months | $1.4B | $19.6B |
| EBITDAEarnings before interest/tax | $155M | $3.3B |
| Net IncomeAfter-tax profit | $96M | $978M |
| Free Cash FlowCash after capex | $91M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +32.5% | +25.6% |
| Operating MarginEBIT ÷ Revenue | +9.7% | +9.3% |
| Net MarginNet income ÷ Revenue | +6.7% | +5.0% |
| FCF MarginFCF ÷ Revenue | +6.4% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.6% | -0.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.5% | +8.5% |
Valuation Metrics
At 11.8x trailing earnings, FMS trades at a 40% valuation discount to ADUS's 19.9x P/E. Adjusting for growth (PEG ratio), ADUS offers better value at 0.99x vs FMS's 2.32x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ADUSAddus HomeCare Co… | FMSFresenius Medical… |
|---|---|---|
| Market CapShares × price | $1.9B | $13.6B |
| Enterprise ValueMkt cap + debt − cash | $2.0B | $24.4B |
| Trailing P/EPrice ÷ TTM EPS | 19.87x | 11.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.01x | 9.89x |
| PEG RatioP/E ÷ EPS growth rate | 0.99x | 2.32x |
| EV / EBITDAEnterprise value multiple | 13.19x | 6.33x |
| Price / SalesMarket cap ÷ Revenue | 1.35x | 0.59x |
| Price / BookPrice ÷ Book value/share | 1.76x | 0.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ADUS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $7 for FMS. ADUS carries lower financial leverage with a 0.19x debt-to-equity ratio, signaling a more conservative balance sheet compared to FMS's 0.76x. On the Piotroski fundamental quality scale (0–9), ADUS scores 7/9 vs FMS's 5/9, reflecting strong financial health.
| Metric | ADUSAddus HomeCare Co… | FMSFresenius Medical… |
|---|---|---|
| ROE (TTM)Return on equity | +8.8% | +6.8% |
| ROA (TTM)Return on assets | +6.7% | +3.2% |
| ROICReturn on invested capital | +8.8% | +5.6% |
| ROCEReturn on capital employed | +10.9% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.19x | 0.76x |
| Net DebtTotal debt minus cash | $127M | $9.2B |
| Cash & Equiv.Liquid assets | $82M | $1.6B |
| Total DebtShort + long-term debt | $209M | $10.8B |
| Interest CoverageEBIT ÷ Interest expense | 11.40x | 6.84x |
Total Returns (with DRIP)
A $10,000 investment in ADUS five years ago would be worth $10,104 today (with dividends reinvested), compared to $7,718 for FMS. Over the past 12 months, ADUS leads with a +8.1% total return vs FMS's +0.2%. The 3-year compound annual growth rate (CAGR) favors FMS at 9.1% vs ADUS's -1.6% — a key indicator of consistent wealth creation.
| Metric | ADUSAddus HomeCare Co… | FMSFresenius Medical… |
|---|---|---|
| YTD ReturnYear-to-date | -2.9% | -0.2% |
| 1-Year ReturnPast 12 months | +8.1% | +0.2% |
| 3-Year ReturnCumulative with dividends | -4.7% | +29.7% |
| 5-Year ReturnCumulative with dividends | +1.0% | -22.8% |
| 10-Year ReturnCumulative with dividends | +356.1% | -28.5% |
| CAGR (3Y)Annualised 3-year return | -1.6% | +9.1% |
Risk & Volatility
FMS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than ADUS's 0.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADUS currently trades 83.2% from its 52-week high vs FMS's 77.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADUSAddus HomeCare Co… | FMSFresenius Medical… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.41x | 0.40x |
| 52-Week HighHighest price in past year | $124.44 | $30.46 |
| 52-Week LowLowest price in past year | $88.96 | $20.95 |
| % of 52W HighCurrent price vs 52-week peak | +83.2% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 41.0 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 173K | 518K |
Analyst Outlook
Wall Street rates ADUS as "Buy" and FMS as "Hold". Consensus price targets imply 28.2% upside for ADUS (target: $133) vs 19.4% for FMS (target: $28).
| Metric | ADUSAddus HomeCare Co… | FMSFresenius Medical… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $132.75 | $28.00 |
| # AnalystsCovering analysts | 15 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | 3 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | 100 | 128.31 | +28.3% |
| Fresenius Medical C… (FMS) | 100 | 56.36 | -43.6% |
Addus HomeCare Corp… (ADUS) returned +1% over 5 years vs Fresenius Medical C… (FMS)'s -23%. A $10,000 investment in ADUS 5 years ago would be worth $10,104 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | $401M | $1.4B | +255.0% |
| Fresenius Medical C… (FMS) | $17.0B | $19.6B | +15.3% |
Addus HomeCare Corporation's revenue grew from $401M (2016) to $1.4B (2025) — a 15.1% CAGR. Fresenius Medical Care AG & Co. KGaA's revenue grew from $17.0B (2016) to $19.6B (2025) — a 1.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | 3.0% | 6.7% | +124.7% |
| Fresenius Medical C… (FMS) | 6.9% | 5.0% | -28.2% |
Addus HomeCare Corporation's net margin went from 3% (2016) to 7% (2025). Fresenius Medical Care AG & Co. KGaA's net margin went from 7% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | 29.7 | 20.6 | -30.6% |
| Fresenius Medical C… (FMS) | 25.3 | 14.2 | -43.9% |
Addus HomeCare Corporation has traded in a 21x–56x P/E range over 9 years; current trailing P/E is ~20x. Fresenius Medical Care AG & Co. KGaA has traded in a 10x–39x P/E range over 9 years; current trailing P/E is ~12x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | 1.04 | 5.21 | +401.0% |
| Fresenius Medical C… (FMS) | 1.87 | 1.68 | -10.2% |
Addus HomeCare Corporation's EPS grew from $1.04 (2016) to $5.21 (2025) — a 20% CAGR. Fresenius Medical Care AG & Co. KGaA's EPS grew from $1.87 (2016) to $1.68 (2025) — a -1% CAGR.
Chart 6Free Cash Flow — 5 Years
Addus HomeCare Corporation generated $0M FCF in 2025 (-100% vs 2021). Fresenius Medical Care AG & Co. KGaA generated $0M FCF in 2025 (-100% vs 2021).
ADUS vs FMS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ADUS or FMS a better buy right now?
Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate Addus HomeCare Corporation (ADUS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ADUS or FMS?
On trailing P/E, Fresenius Medical Care AG & Co. KGaA (FMS) is the cheapest at 11.8x versus Addus HomeCare Corporation at 19.9x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 9.9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Addus HomeCare Corporation wins at 0.74x versus Fresenius Medical Care AG & Co. KGaA's 1.94x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ADUS or FMS?
Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +1.0%, compared to -22.8% for Fresenius Medical Care AG & Co. KGaA (FMS). A $10,000 investment in ADUS five years ago would be worth approximately $10K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADUS returned +356.1% versus FMS's -28.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ADUS or FMS?
By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co. KGaA (FMS) is the lower-risk stock at 0.40β versus Addus HomeCare Corporation's 0.41β — meaning ADUS is approximately 2% more volatile than FMS relative to the S&P 500. On balance sheet safety, Addus HomeCare Corporation (ADUS) carries a lower debt/equity ratio of 19% versus 76% for Fresenius Medical Care AG & Co. KGaA — giving it more financial flexibility in a downturn.
05Which has better profit margins — ADUS or FMS?
Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.7% net margin versus 5.0% for Fresenius Medical Care AG & Co. KGaA — meaning it keeps 6.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9.7% versus 9.3% for FMS. At the gross margin level — before operating expenses — ADUS leads at 32.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ADUS or FMS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Addus HomeCare Corporation (ADUS) is the more undervalued stock at a PEG of 0.74x versus Fresenius Medical Care AG & Co. KGaA's 1.94x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 9.9x forward P/E versus 15.0x for Addus HomeCare Corporation — 5.1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADUS: 28.2% to $132.75.
07Which pays a better dividend — ADUS or FMS?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ADUS or FMS better for a retirement portfolio?
For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.41), +356.1% 10Y return). Both have compounded well over 10 years (ADUS: +356.1%, FMS: -28.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ADUS and FMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: ADUS is a small-cap quality compounder stock; FMS is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.